Irritable bowel syndrome affects roughly 1 in 7 people worldwide, with a global prevalence of about 14.1% based on a 2024 meta-analysis covering 52 countries. In the United States alone, an estimated 10 to 15 percent of adults experience IBS symptoms, making it one of the most frequently diagnosed gastrointestinal conditions. Yet despite how widespread it is, the majority of people living with symptoms have never received a formal diagnosis.
Most People With IBS Don’t Know They Have It
The gap between how many people have IBS and how many know it is striking. While 10 to 15 percent of U.S. adults report IBS symptoms, only 5 to 7 percent have actually been diagnosed, according to the American College of Gastroenterology. That means roughly half of the people who meet the criteria for IBS have never had it identified by a doctor.
Part of the reason is that IBS symptoms, including abdominal pain, bloating, and changes in bowel habits, overlap with many other conditions. There’s no blood test or scan that confirms IBS. Diagnosis relies on patterns of symptoms over time, which means people who chalk up their discomfort to stress, diet, or “a sensitive stomach” may never seek evaluation. The diagnostic criteria themselves have also shifted over the years, which affects how many people qualify depending on the standard being used.
How Diagnostic Standards Change the Numbers
Doctors use a standardized checklist called the Rome criteria to diagnose IBS, and the version they use makes a real difference in prevalence estimates. The older Rome III criteria cast a wider net: in one large study, 31% of patients screened met Rome III thresholds for IBS. When the stricter Rome IV criteria were applied to the same group, only 17.7% qualified. Rome IV requires that abdominal pain be directly related to bowel movements and occur at least one day per week, which excludes people with milder or less frequent symptoms. If you’ve read conflicting statistics about how common IBS is, the diagnostic version being used is often the reason.
Women Are Significantly More Likely to Be Affected
IBS is not equally distributed between men and women. Pooled data from large studies consistently show that women are diagnosed at higher rates, with one major meta-analysis of over 162,000 people finding a prevalence of 14.0% in women compared to 8.9% in men. That translates to women being about 1.7 times more likely to have IBS overall.
The disparity is even more pronounced after a gastrointestinal infection. Women are 2.2 times more likely than men to develop what’s called post-infectious IBS, a form that begins after a bout of food poisoning or gastroenteritis. Hormonal fluctuations likely play a role, as many women report that their IBS symptoms worsen around menstruation. Differences in gut motility, pain sensitivity, and how the brain processes signals from the digestive system also contribute to the gap.
Age Makes a Difference
IBS is most commonly diagnosed in younger adults. U.S. data from community health centers shows that 12% of adults aged 18 to 44 were identified with IBS, compared to 7% of those aged 45 to 64 and just 5% of people 65 and older. This pattern holds across most studies globally. That doesn’t necessarily mean older adults outgrow IBS. Some develop coping strategies or dietary changes over time, and others may be reclassified with different diagnoses as new conditions emerge with aging. But the peak burden falls squarely on working-age adults in their 20s through 40s.
Prevalence Varies by Region
Where you live affects your likelihood of an IBS diagnosis, though the reasons are complex. Latin America reports the highest regional prevalence at 17.5%, followed by Asia at 9.6%. North America and Europe come in at about 7.1%, and the Middle East and Africa at 5.8%. Among individual countries, the UK, China, and Japan stand out as having particularly high rates.
These numbers reflect more than biology. Access to healthcare, cultural attitudes toward digestive complaints, dietary patterns, and how actively researchers have studied the condition in a given region all shape the data. Countries where people are more likely to seek medical care for gut symptoms will naturally report higher diagnosis rates. In regions with limited gastroenterology infrastructure, many cases simply go uncounted.
The Three Main Subtypes
IBS isn’t a single experience. It’s grouped into subtypes based on the dominant bowel pattern, and the distribution is fairly even among adults. Globally, the mixed subtype (alternating between constipation and diarrhea) is the most common, accounting for about 31.4% of cases. Diarrhea-predominant IBS makes up 26.5%, and constipation-predominant IBS accounts for 26.1%. A smaller group, around 8.3%, falls into an “unsubtyped” category where no clear pattern emerges.
Your subtype matters because it determines which treatments and dietary strategies are most likely to help. Someone whose primary problem is frequent loose stools will need a different approach than someone dealing with chronic constipation, even though both carry the same IBS diagnosis.
Stress, Anxiety, and Depression Are Strongly Linked
Psychological factors don’t just make IBS worse. They’re among the strongest risk factors for developing it in the first place. A 2024 meta-analysis found that people with anxiety were 2.93 times more likely to have IBS, those with depression were 2.24 times more likely, and those reporting high stress levels were 2.47 times more likely. Interestingly, factors you might expect to matter, like smoking, alcohol use, and education level, showed no significant association.
This connection runs in both directions. The gut and brain communicate constantly through a network of nerves, hormones, and immune signals. Chronic stress can alter gut motility and increase sensitivity to pain in the intestines. At the same time, living with unpredictable digestive symptoms generates its own anxiety, creating a cycle that feeds itself. This is why effective IBS management often involves addressing psychological health alongside digestive symptoms.
The Financial Burden Is Substantial
IBS carries a real economic cost. People with diarrhea-predominant IBS in the U.S. spend an average of $13,038 per year on healthcare, with more than half of that going toward office visits, diagnostic tests, and lab work. Compared to similar patients without IBS, that’s roughly $2,268 more per year in additional healthcare spending after adjusting for other health conditions.
The costs extend beyond doctor visits. Prescriptions account for about 20% of direct spending, and emergency department visits add another 8.5%. These figures don’t capture indirect costs like missed workdays or reduced productivity, which are widely recognized as a significant additional burden. For a condition that peaks during prime working years, the cumulative financial impact across a lifetime can be considerable.